Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice
https://doi.org/10.37489/2588-0519-2020-S4-115-119
Abstract
Global experience with the clinical use of favipiravir is very limited. Its safety is for further study. Prevention of teratogenic effects (mandatory pregnancy test before starting therapy, compliance with effective contraception by both women and men), control of the level of uric acid, transaminases and ECG are of fundamental importance. Alertness is needed for new, insufficiently documented or previously unreported adverse events such as motor disturbances and falls. Patients should be fully informed about all the risks of therapy before starting it. Special attention is required to timely fill out the approved forms of notifications on the development of HP and report them in time according to the Order of the Federal Service for Surveillance in Healthcare of February 15, 2017 No. 1071 «On approval of the Procedure for the implementation of pharmacovigilance.»
About the Authors
Yu. Yu. Kiselev
Oslo Metropolitan University
Norway
Norway
Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet
Oslo
A. V. Matveev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320
Moscow
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. State register of drugs. (In Russ). Доступно по: https://clck.ru/RDVZf Ссылка активна на 24.09.2020
2. The provisional guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 7th ed., Moscow: Ministry of health of the Russian Federation, 2020. 166 p. (In Russ).
3. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against lifethreatening RNA virus infections. Pharmacol Ther. 2020 May;209:107512. DOI: 10.1016/j.pharmthera.2020.107512
4. 200mg [Internet]. [cited 2020 September 27]; Available from: https://clck.ru/RDVbo
5. Doi Y et al. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020 Sep 21;AAC.01897-20. DOI: 10.1128/AAC.01897-20
6. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir — a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020 Apr 30;6(2):45-51. DOI: 10.1016/S2055-6640(20)30016-9
7. Ruzhentsova TA et al. Potential for etiotropic therapy of SARS-CoV-2-induced coronavirus disease in outpatients. Medical Opponent = Meditsinskii Opponent. 2020;1(9):48-58. (In Russ).
8. Avigan [Internet]. [cited 2020 June 04]; Available https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw
9. Preliminary Report of the Favipiravir Observational Study in Japan [Internet]. [cited 2020 September 24]; Available from: https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf
10. Персональная коммуникация
11. Yaylaci S et al. The effects of favipiravir on hematological parameters of covid-19 patients. Rev Assoc Med Bras (1992). 2020 Sep 21;66Suppl 2(Suppl 2):65-70. DOI: 10.1590/1806-9282.66.S2.65
12. Kumagai Y et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther. 2015 Oct;53(10):866-74. Doi: 10.5414/CP202388
13. Chinello P et al. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034. doi: 10.1371/journal.pntd.000603.
14. Michaud V et al. Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs. Clin Transl Sci. 2020 Sep 5. DOI: 10.1111/cts.12882
15. (No Title) [Internet]. [cited 2020 September 27]; Available from: https://www.info.pmda.go.jp/kaiteip/20180821A001/05.pdf
16. PMDA — Report on the Deliberation Results [Internet]. [cited 2020 June 04]; Available from: https://www.pmda.go.jp/files/000210319.pdf
17. Du Y-X, Chen X-P. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020 Aug;108(2):242-247. DOI: 10.1002/cpt.1844
18. Singh TU et al. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020 Sep 5;1-30. DOI: 10.1007/s43440-020-00155-6
19. Koshi E et al. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. CEN Case Rep. 2020 Sep 17;1-6. DOI: 10.1007/s13730-020-00534-1
20. Soh M et al. Neuroleptic malignant syndrome in patients with COVID-19. Am J Emerg Med. 2020 May 22;S0735-6757(20)30384-3. DOI: 10.1016/j.ajem.2020.05.042
21. WHO R&D Blueprint COVID-19: Informal consultation on the potential inclusion of Favipiravir in a clinical trial [Internet]. [cited 2020 June 04]; Available from: https://clck.ru/RDJmr
Supplementary files
|
1. Пояснения к «Мониторингу безопасности применения фавипиравира: управление рисками развития нежелательных лекарственных реакций в клинической практике» | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(99KB)
|
Indexing metadata ▾ | |
Review
For citations:
Kiselev Yu.Yu., Matveev A.V., Mirzaev K.B., Sychev D.A. Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):115-119. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-115-119
Views:
8450
Email this article 